Pathologic, Clinical, and Epidemiologic Characteristics of Invasive Lobular Breast Carcinoma and a Review of Studies Evaluating its Association with Hormone Replacement Therapy

Potter JD, Cerhan JR, Sellers TA, et al (1995) Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women’s Health Study: how many types of breast cancer are there? Cancer Epidemiol Biomarker Prev 4:319–326.Google Scholar

Schnitt S, Connolly J, Recht A, et al (1989) Influence of infiltrating lobular histology on local tumor control in breast cancer patients treated with conservative surgery and radiotherapy. Cancer 64:448–454.PubMedCrossRefGoogle Scholar

Sastre-Garau X, Jouve M, Asselain B, et al (1996) Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77:113–120.PubMedCrossRefGoogle Scholar

Davis RP, Nora PF, Kooy RG, et al (1979) Experience with lobular carcinoma of the breast: Emphasis on recent aspects of management. Arch Surg 114:485.PubMedGoogle Scholar

Acs G, Lawton TJ, Rebbeck TR, et al (2001) Differential expression of ecadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 115:85–98.PubMedCrossRefGoogle Scholar

Stierer M, Rosen H, Weber R, et al (1993) Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer: Correlation of histopathology and prognostic factors. Ann Surg 218:13–21.PubMedGoogle Scholar

Oyama T, Kashiwabara K, Yoshimoto K, et al (1998) Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res 58:2876–2880.PubMedGoogle Scholar

Domagala W, Markiewski M, Kubiak R, et al (1993) Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchow Archiv 423:497–502.CrossRefGoogle Scholar

Coradini D, Pellizzaro C, Veneroni S, et al (2002) Infiltrating ductal and lobular breast carcinomas are characterized by different interrelationships among markers related to angiogenesis and hormone dependence. Brit J Cancer 87:1105–1111.PubMedCrossRefGoogle Scholar

Lee AHS, Dublin EA, Bobrow LG, et al (1998) Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J Pathol 185:394–401.PubMedCrossRefGoogle Scholar

Nishizaki T, Chew K, Chu L, et al (1997) Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 74:513–517.PubMedCrossRefGoogle Scholar

Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, et al (2001) Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 193:40–47.PubMedCrossRefGoogle Scholar

Dixon J, Anderson T, Page D, et al (1982) Infiltrating lobular carcinoma of the breast. Histopathology 6:149–161.PubMedGoogle Scholar

Yeatman TJ, Cantor AB, Smith TJ, et al (1995) Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg 222:549–559.PubMedGoogle Scholar

Silverstein MJ, Lewinsky BS, Waisman JR, et al (1994) Infiltrating lobular carcinoma: is it different from infiltrating duct carcinoma? Cancer 74:1673–1677.CrossRefGoogle Scholar

Krecke K, Gisvold J (1993) Invasive lobular carcinoma of the breast: Mamographic findings and extent of disease at diagnosis in 184 patients. Am J Roentgenol 161:957–960.Google Scholar

Du Toit RS, Locker AP, Ellis IO, et al (1991) An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncology 17:251–257.Google Scholar

Li CI, Moe RE, Daling JR (2003) Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Int Med 163:2149–2153.CrossRefGoogle Scholar

Li CI, Malone KE, Daling JR (2002) Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarker Prev 11:601–607.Google Scholar

Friedman-Koss D, Crespo CJ, Bellantoni MF, et al (2002) The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988–1994. Menopause 9:264–272.PubMedCrossRefGoogle Scholar

Li CI, Anderson BO, Porter P, et al (2000) Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 88:2561–2569.PubMedCrossRefGoogle Scholar

Li CI, Anderson BO, Daling JR, et al (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289:1421–1424.PubMedCrossRefGoogle Scholar

Verkooijen HM, Fioretta G, Vlastos G, et al (2003) Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 104:778–781.PubMedCrossRefGoogle Scholar

Wysowski DK, Golden L, Burke L (1995) Use of menopausal estrogens and medroxyprogesterone in the United States, 1982–1992. Obstet Gynecol 85:6–10.PubMedCrossRefGoogle Scholar

Daling JR, Malone KE, Doody DR, et al (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95:2455–2464.PubMedCrossRefGoogle Scholar

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059.CrossRefGoogle Scholar

Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333.CrossRefGoogle Scholar

Li CI, Weiss NS, Stanford JL, et al (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88:2570–2577.PubMedCrossRefGoogle Scholar

Chen CL, Weiss NS, Newcomb P, et al (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287:734–741.PubMedCrossRefGoogle Scholar

Newcomb PA, Titus-Ernstoff L, Egan KM, et al (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarker Prev 11:593–600.Google Scholar

Newcomer LM, Newcomb PA, Potter JD, et al (2003) Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14:225–233.PubMedCrossRefGoogle Scholar

Li CI, Malone KE, Porter PL, et al (2003) Relationship between long-term use of hormone replacement therapy and risk of breast cancer among women 65–79 years of age. JAMA 289:3254–3263.PubMedCrossRefGoogle Scholar

Colditz GA, Hankinson SE, Hunter DJ, et al (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 332:1589–1593.PubMedCrossRefGoogle Scholar

Ross RK, Paganini-Hill A, Wan PC, et al (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328–332.PubMedCrossRefGoogle Scholar

Steinberg KK, Smith SJ, Thacker SB, et al (1994) Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 5:415–421.PubMedCrossRefGoogle Scholar

Colditz GA, Stampfer MJ, Willett WC, et al (1990) Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 264:2648–2653.PubMedCrossRefGoogle Scholar

Colditz GA, Stampfer MJ, Willett WC, et al (1992) Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses’ Health Study. Cancer Causes Control 3:433–439.PubMedCrossRefGoogle Scholar

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs, Nov 2002 Sub (1973–2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission.Google Scholar

Shi YE, Liu YE, Lippman ME, et al (1994) Progestins and antiprogestins in mammary tumor growth and metastasis. Human Reproduction 9:162–173.PubMedGoogle Scholar

Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissue. Endocrine Rev 18:502–519.CrossRefGoogle Scholar

Meyer JS (1977) Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Hum Pathol 8:67–81.PubMedGoogle Scholar

Masters JRW, Drife JO, Scarisbrick JJ (1977) Cyclic variation of DNA synthesis in human breast epithelium. J Natl Cancer Inst 58:1263–1265.PubMedGoogle Scholar

Ferguson DJP, Anderson TJ (1981) Morphological evaluation of cell turnover in relation to the menstrual cycle in the “resting” human breast. Br J Cancer 44:177–181.PubMedGoogle Scholar

Anderson TJ, Ferguson DJP, Raab GM (1982) Cell turnover in the “resting” human breast: influence of parity, contraceptive pill, age, and laterality. Br J Cancer 46:376–382.PubMedGoogle Scholar

Haslam SZ (1988) Progesterone effects on deoxyribonucleic acid synthesis in normal mouse mammary glands. Endocrinology 122:464–470.PubMedCrossRefGoogle Scholar

Lydon JP, DeMayo FJ, Funk CR, et al (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9:2266–2278.PubMedGoogle Scholar

Musgrove EA, Lee CS, Sutherland RL (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11:5032–5043.PubMedGoogle Scholar

Musgrove WA, Hamilton JA, Lee CS, et al (1991) Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13:3577–3587.Google Scholar

Murphy LC, Murphy LJ, Dubik D, et al (1988) Epidermal growth factor gene expression in human breast cancer cells: regulation of expression by progestins. Cancer Res 46:4555–4560.Google Scholar

Murphy LJ, Sutherland RL, Stead B, et al (1986) Progestin regulation of epidermal growth factor receptor in human mammary carcinoma cells. Cancer Res 46:728–734.PubMedGoogle Scholar

Murphy LC, Murphy LK, Shiu RPC (1988) Progestin regulation of EGF-receptor mRNA accumulation in T-47D human breast cancer cells. Biochem Biophys Res Commun 150:192–196.PubMedCrossRefGoogle Scholar

Murphy LC, Dotzlaw H (1989) Regulation of transforming growth factor α and transforming growth factor β messenger ribonucleic acid abundance in T-47D human breast cancer cells. Mol Endocrinol 3:611–617.PubMedCrossRefGoogle Scholar

Lange C, Richer JK, Horwitz KB (1999) Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Molec Endocrinol 13:829–836.CrossRefGoogle Scholar

Kastner P, Krust A, Turcotte B, et al (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603–1614.PubMedGoogle Scholar

Shyamala G, Yang X, Silberstein G, et al (1998) Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary gland. Proc Nat Acad Sci USA 95:696–701.PubMedCrossRefGoogle Scholar

Shyamala G, Yang X, Cardiff RD, et al (2000) Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Nat Acad Sci USA 97:3044–3049.PubMedCrossRefGoogle Scholar

Richer JK, Jacobsen BM, Manning NG, et al (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277:5209–5218.PubMedCrossRefGoogle Scholar

Ariga N, Suzuki T, Moriya T, et al (2001) Progesterone receptor A and B isoforms in the human breast and its disorders. Jpn J Cancer Res 92:302–308.PubMedGoogle Scholar